Heckle this!Cangene named as one of Canada's 50 Best-Managed Companies
Monday January 12, 4:31 pm ET
Listed TSX, Symbol: CNJ
TORONTO and WINNIPEG, Jan. 12 /CNW/ - Cangene is pleased to report that it is a winner in Canada's 50 Best Managed Companies program for 2003, a program sponsored by Deloitte & Touche, CIBC, the National Post and Queen's School of Business.
"We are extremely pleased to receive this type of recognition," said Dr. John Langstaff, Cangene's president and CEO. "This program recognizes the accomplishments of our entire organization and is a tribute to our employees in Canada and the U.S.," he added.
"Over the past 11 years, Canada's 50 Best Managed Companies program has recognized some of the most innovative and best managed companies in Canada, and we are delighted to celebrate the accomplishments of Cangene Corporation," said Tony Grnak, partner at Deloitte, a national sponsor of the 50 Best program.
Established in 1993, the Canada's 50 Best Managed Companies program recognizes companies that have demonstrated exceptional ability and aptitude in all areas of management and best business practices. To be recognized as one of the 50 Best, companies must complete a comprehensive questionnaire and an extensive, in-depth interview process that are evaluated by an independent judging panel to assess and examine its management practices. The panel evaluated how companies address a broad spectrum of business issues and facilitate growth. Additional information about the program can be found at www.canadas50best.com.
Cangene is one of Canada's largest biotechnology companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene carries out research and development in Mississauga, Ontario and Winnipeg. It uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has two approved products, two products that have been submitted for regulatory review, and a significant clinical trial program including a Vaccinia immunoglobulin ("VIG") and human growth hormone, which is nearing regulatory submission.
Cangene is also expanding its contract research and manufacturing businesses using its drug-manufacturing expertise and the resources of Chesapeake Biological Laboratories, Inc. (a wholly-owned subsidiary). The Company's internationally-compliant, ISO 9001-registered manufacturing facilities are located in Winnipeg, Manitoba and Baltimore, Maryland. Cangene's website, www.cangene.com, includes product and investor information, including past news releases. Chesapeake's website is www.cblinc.com.
https://biz.yahoo.com/cnw/040112/cangene_50_best_comp_1.html